Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 8 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in LNAI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LNAI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 20, 2025 | Van Tilburg MauriceDirector | Stock Award(Grant) at price 0.00 per share. | 250K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.6 | -52.4 | 10.0 | -19.1 | 16.7 | 6.2 | -40.7 | 17.3 | -35.4 | -29.9 | −85.4% | ||
| 2025 | -10.3 | 31.1 | -44.8 | -33.7 | -13.9 | -6.8 | -11.4 | -7.0 | -40.3 | -38.7 | 35.6 | -25.3 | −89.4% |
| 2024 | 37.9 | -41.0 | 2.7 | -40.4 | -5.7 | 17.4 | -58.3 | -17.9 | -19.4 | 10.1 | 42.1 | 10.6 | −73.6% |
| 2023 | 18.4 | -15.6 | -11.2 | 24.6 | -21.1 | -36.9 | 14.6 | 381.5 | 42.8 | -36.5 | 17.3 | -4.8 | +207.8% |
| 2022 | -32.6 | 54.0 | 9.1 | -6.8 | -31.6 | -63.3 | 19.2 | 7.4 | -26.7 | 12.2 | -25.9 | -31.6 | −85.9% |
| 2021 | 28.5 | -6.6 | 0.0 | -4.5 | 20.4 | 22.1 | 0.2 | 48.2 | -8.8 | 38.5 | 34.7 | -41.9 | +147.1% |
| 2020 | -11.8 | -26.4 | -8.0 | 14.0 | 3.8 | 18.6 | -8.6 | 6.0 | -12.3 | -14.8 | -4.9 | 1.7 | −41.2% |
| 2019 | -7.4 | 9.6 | -2.3 | -11.4 | 7.8 | -32.1 | 8.7 | -3.9 | 17.0 | 3.6 | 1.9 | -13.6 | −28.3% |
| 2018 | -7.6 | -9.1 | 5.0 | -36.8 | 20.5 | 12.5 | 29.8 | -2.4 | 13.2 | 8.5 | +17.6% |
No analyst coverage for this instrument.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.